14.745  0.005 (0.03%)		06-28 15:59
Open: 14.74 High: 14.75 Volume: 2,839,350		Pre. Close: 14.74 Low: 14.74 Market Cap: 1,870(M)

Short term
Mid term
Targets	6-month :	17.23	1-year :	20.13
Resists	First :	14.76	Second :	17.23
Pivot price	14.71
Supports	First :	14.53	Second :	14.39
MAs	MA(5) :	14.73	MA(20) :	14.67
	MA(100) :	11.36	MA(250) :	10.31
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	94.5	D(3) :	94.5
RSI	RSI(14): 78.2
52-week	High :	14.76	Low :	6.38

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BLU ] has closed below upper band by 38.9%. Bollinger Bands are 88.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.77 - 14.85	14.85 - 14.91
Low:	14.53 - 14.64	14.64 - 14.72
Close:	14.6 - 14.75	14.75 - 14.87

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Fri, 16 Jun 2023
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders - Business Wire

Tue, 16 May 2023
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition - Yahoo Finance

Fri, 12 May 2023
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Business Wire

Wed, 10 May 2023
Should You Buy Bellus Health (BLU) After Golden Cross? - Yahoo Singapore News

Wed, 19 Apr 2023
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK - Yahoo Finance

Tue, 18 Apr 2023
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	127 (M)
Held by Insiders	9.213e+007 (%)
Held by Institutions	10.2 (%)
Shares Short	7,150 (K)
Shares Short P.Month	0 (K)

EPS	-8.999e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-602 %
Return on Assets (ttm)	46.6 %
Return on Equity (ttm)	-16.8 %
Qtrly Rev. Growth	15000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-89 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-1.42

Dividend	0
Forward Dividend	6.65e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.